POLYPID LTD
PYPDNASDAQTrading Snapshot
- Day Range
- $4.67 – $4.78
- 52-Week Range
- $3.06 – $5.73
- Volume
- $1.89B
- Avg Volume
- $1.82B
- Shares Outstanding
- 19.2M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.91
- Dividend Yield
- —
Why Investors Own PYPD
- ✓High-growth profile — revenue up +48.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About POLYPID LTD
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28
The FDA did not identify any filing review issues and set a Prescription Drug User Fee Act ("PDUFA") target action date of November 28, 2026, approximately one quarter ahead of the Company’s previously
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's regular session. The company's market cap stands at $36.8 million. Wellgistics Health (NASDAQ:WGRX) shares increased
HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $13 price target.
PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront Payment
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has